Jentadueto (Linagliptin/Metformin) for Diabetes

Overview
Jentadueto is a prescription drug approved by the Food and Drug Administration (FDA) to help improve blood glucose control in adults with type 2 diabetes. Jentadueto is considered an adjunct treatment to diet and exercise.

Jentadueto is a combination drug composed of the drugs Linagliptin, the active ingredient in Tradjenta, and Metformin. Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor. Linagliptin is believed to work by lowering blood glucose levels when they are elevated. Metformin is a biguanide. Metformin is believed to work by decreasing the amount of glucose produced by the liver and making the muscle tissue more sensitive to insulin.

How do I take it?
Prescribing information states that Jentadueto is generally taken twice daily with meals.

Jentadueto comes in tablet form.

Side effects
The FDA-approved label for Jentadueto lists common side effects including cold symptoms, diarrhea, and hypoglycemia (low blood glucose).

Rare but serious side effects listed for Jentadueto include lactic acidosis (when the tissues and blood become too acidic), pancreatitis, kidney problems, and systemic allergic reaction.

For answers to frequently asked questions about exposure to Metformin during pregnancy and breastfeeding, visit the experts at MothertoBaby.org.